SHASQI
Shasqi is leading the development of therapeutics leveraging click chemistry to get active cancer treatments to tumors with its proprietary CAPAC™ (Click Activated Protodrugs Against Cancer) platform. The technology is based on localizing a click chemistry reagent in the tumor area, which then activates a second agent, a systemically infused protodrug. When the two ‘click’, a powerful localized therapy is activated at the tumor, while keeping its systemic exposure levels below toxic thresholds. We have already proven that our platform works in humans, which opens up an array of future possibilities for click-chemistry based therapies.
SHASQI
Industry:
Biotechnology Emergency Medicine Health Care Medical
Founded:
2015-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.shasqi.com
Total Employee:
11+
Status:
Active
Total Funding:
64.02 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager Global Site Tag Microsoft Exchange Online
Similar Organizations
Entrada Therapeutics
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
Moderna Therapeutics
Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.
Praxis Precision Medicines
Praxis develops therapies for CNS disorders by leveraging genetic insights into neuronal imbalances, targeting rare to common conditions.
Redcliffe Labs
Redcliffe is a one-stop diagnostic platform offering a wide selection of tests to choose from and delivering care closer to the customer.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Advisors List
Board_member
Current Employees Featured
Glenn Prestwich Consultant @ Shasqi
Consultant
2018-01-01
José M. Mejía Oneto Chief Executive Officer @ Shasqi
Chief Executive Officer
2015-01-01
Kirsten Abma Communications and Business Operations Manager @ Shasqi
Communications and Business Operations Manager
2020-01-01
Esteban Abella Chief Medical Officer @ Shasqi
Chief Medical Officer
2022-05-15
Founder
Investors List
National Cancer Institute
National Cancer Institute investment in Grant - Shasqi
William J. Rieflin
William J. Rieflin investment in Series B - Shasqi
Juan Jaen
Juan Jaen investment in Series B - Shasqi
National Cancer Institute
National Cancer Institute investment in Grant - Shasqi
Endpoint Ventures
Endpoint Ventures investment in Series A - Shasqi
Y Combinator
Y Combinator investment in Series A - Shasqi
Y Combinator
Y Combinator investment in Pre Seed Round - Shasqi
Newest Events participated
Participated in Y Combinator Winter 2015 Demo Day
on 2015-03-23 as exhibitor
Key Employee Changes
Official Site Inspections
http://www.shasqi.com Semrush global rank: 5.6 M Semrush visits lastest month: 1.51 K
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 75.2.70.75
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Shasqi"
About Shasqi
Shasqi’s leadership has diverse backgrounds, a wealth of experience, and is supported by a Scientific Advisory Board of distinguished oncology leaders. Learn more. From concept to …See details»
Shasqi - Crunchbase Company Profile & Funding
Organization. Shasqi . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... A partnership to …See details»
Shasqi
"Three years after demonstrating the first-ever in vivo use of click chemistry by safely delivering 12 times the standard dose of doxorubicin directly to tumors, Shasqi is again pushing boundaries.Its CAPAC platform, which initially relied …See details»
Shasqi - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors ... Pre Seed Round - Shasqi . 1: …See details»
SHASQI, INC. Company Profile | San Francisco, CA | Competitors ...
Find company research, competitor information, contact details & financial data for SHASQI, INC. of San Francisco, CA. Get the latest business insights from Dun & Bradstreet.See details»
Shasqi - Company Profile - Tracxn
Feb 24, 2025 Shasqi - Developer of local drug activation technology for tumors. Raised a total funding of $60M over 7 rounds from 7 investors. Founded by Jose M Mejia Oneto and Jose …See details»
Shasqi Company Profile - Office Locations, Competitors, Revenue …
Shasqi has 5 employees at their 1 location and $10.12 m in total funding,. See insights on Shasqi including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
Shasqi - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Shasqi . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 5. Number of Board …See details»
SHASQI, INC - VentureRadar
" Shasqi is a privately held, clinical stage biotechnology company whose mission is to enable patients to beat cancer without poisoning their bodies. Shasqi leverages its proprietary Click …See details»
Shasqi - Overview, News & Similar companies | ZoomInfo.com
Mar 10, 2024 Shasqi is a privately held, clinical-stage biotechnology company whose mission is to enable patients to beat cancer with tumor-localized therapies. Shasqi leverages its …See details»
Shasqi - LinkedIn
Shasqi is a biotech company whose mission is to revolutionize cancer treatment with click chemistry, a 2022 Nobel Prize winning technology. Our unique CAPAC® (Click Activated …See details»
Shasqi
Our proprietary Click Activated Protodrugs Against Cancer (CAPAC ®) platform is a pre-targeting approach, capturing payloads at the tumor via in-vivo click chemistry, a 2022 Nobel Prize …See details»
Shasqi - UCSF Rosenman Institute
Sep 20, 2022 Shasqi Founders Pledge Our technology, based on bioorthogonal chemistry, enables the activation of small molecule drugs at the local tissue-level, improving both their …See details»
Shasqi snatches $50M for chemotherapy-boosting treatments …
Nov 11, 2021 Shasqi presented proof-of-concept data for SQ3370 from a phase 1 study at the European Society for Medical Oncology Congress earlier this year. At the time, the biotech …See details»
Shasqi Awarded a Second NCI Grant of $1.9M to Accelerate the ...
Dec 8, 2021 Shasqi leverages its proprietary CAPAC Platform to develop precision oncology therapeutics designed to deliver unprecedented doses precisely focused at the tumor with an …See details»
SHASQI, INC - VentureRadar
Shasqi is a privately held, clinical stage biotechnology company whose mission is to enable patients to beat cancer without poisoning their bodies. Shasqi leverages its proprietary Click …See details»
Shasqi's platform
Here's how CAPAC works. CAPAC separates the binder from the payload and uses click chemistry, a novel technology that won the 2022 Nobel Prize in Chemistry, to reunite the two …See details»
Shasqi, Inc. (Shasqi, Inc.) - 药物管线_专利_临床试验_投融营收_最新 …
了解Shasqi, Inc. (Shasqi, Inc.)公司的药物管线，治疗领域，技术平台，以及它的1项临床试, 12篇新闻和7篇文献，疾病领域:肿瘤，血液及淋巴系统疾病，免疫系统疾病，技术平台:化学药，小 …See details»
Shasqi in the news
Shasqi announces two abstracts accepted for poster presentation at the SITC 39th Annual Meeting, held November 8-10, 2024, in Houston, TX. conference. Oct 10, 2024. 2024 - World …See details»
Shasqi in the news
Shasqi to Present Data on Novel Tumor-Targeted Drug Activation Technology at 2024 American Association for Cancer Research (AACR) Annual Meeting. conference. Mar 17, 2024. 2024 - …See details»